Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0EMQPK
ADC Name
SYD-1875
Synonyms
Anti-5T4 antibody drug conjugate; SYD 1875; SYD-1875; SYD18 75; SYD1875
   Click to Show/Hide
Organization
Synthon BV; Byondis BV
Drug Status
Phase 1 (Terminated)
Indication
In total 1 Indication(s)
Solid tumor
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
1.9
Structure
Antibody Name
SYD1594
  Antibody Info 
Antigen Name
Trophoblast glycoprotein (TPBG)
  Antigen Info 
Payload Name
seco-DUBA
  Payload Info 
Therapeutic Target
Human Deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
Mal-PEG2-Val-Cit-PABA-Cyclization Spacer
  Linker Info 
Conjugate Type
Reactive Cysteines
Combination Type
duocarmazine
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT04202705
Phase 1
A first-in-human dose-escalation and expansion study with the antibody-drug conjugate SYD1875 to evaluate the safety, pharmacokinetics and efficacy in patients with 5T4-expressing locally advanced or metastatic solid tumours.

   Click to Show/Hide
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT04202705  Clinical Status Phase 1
Clinical Description A first-in-human dose-escalation and expansion study with the antibody-drug conjugate SYD1875 to evaluate the safety, pharmacokinetics and efficacy in patients with 5T4-expressing locally advanced or metastatic solid tumours.
References
Ref 1 A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With 5T4-expressing Locally Advanced or Metastatic Solid Tumours